Abstract 425P
Background
Palbociclib, ribociclib and abemaciclib play an important role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) BC based on their impressive efficacy; however, there seem to be some differences in toxicity profiles which can adversely affect their QoL. This study aims to evaluate health-related QoL (HRQoL) in advanced BC patients treated with CDK4/6i with the help of digital apps.
Methods
HRQoL was assessed in women with HR+/HER2- metastatic BC treated with CDK4/6i plus endocrine therapy using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire via online platform in Spanish patients with a cut-off date of August 2022.
Results
A total of 264 patients were analyzed. 85% had between 40-69 years. 30% were employed. The most used CDK4/6i was palbociclib (46.2%), followed of ribociclib (39.8%) and abemaciclib (14%). 33% had a dose reduction. 69.7% of patients had received chemotherapy previously; of these, 91.8% consider that their QoL is better with CDK4/6i. Of all patients who are undergoing with CDK4/6i, 87.5% feel content with the treatment. Overall scores from the FACT-B questionnaire were comparable between all CDK4/6i (Table). Notably, 45.9% and 37.8% of patients in the abemaciclib group reported diarrhea and nausea, respectively. Better scores were registered in the palbociclib arm for fatigue, pain, insomnia and better sexual enjoyment. Table: 425P
| FACT-B* | Palbociclib | Ribociclib | Abemaciclib | p value |
| N (%) | 122 (46.3%) | 105 (39.7%) | 37 (14%) | |
| Age (%)≤ 39 years40-69 years≥ 70 years | 11 (9.02%)105 (86.07%)6 (4.92%) | 14 (13.33%)89 (84.76%)2 (1.91%) | 7 (18.98%)30 (81.08%)0 | 0,232 |
| Physical well-being, median (range) | 22 (4-28) | 21 (1-28) | 20 (9-27) | 0,431 |
| Social/family well-being, median (range) | 17 (0-27) | 18 (0-24) | 18 (5-26) | 0,48 |
| Emotional well-being, median (range) | 14 (3-24) | 10 (0-18) | 13 (6-20) | 0,005 |
| Functional well-being, median (range) | 13.5 (0-26) | 14 (1-27) | 13 (1-23) | 0,855 |
| Breast cancer subscale, median (range) | 24 (7-39) | 23 (4-35) | 20 (13-32) | 0,027 |
| Total score, median (range) | 90 (24-135) | 86 (29-127) | 83 (53-104) | 0,049 |
*Higher scores indicate a better QoL.
Conclusions
The CDK4/6i play an eminent role in the therapy of advanced BC; nevertheless, the impact of treatment in QoL should be considered in addition to efficacy and safety, especially in the non-curative setting. Our HR-QoL results seems to confirm those obtained in clinical trials. To our knowledge this is the first study about HR-QoL in HR+/HER2- BC patients treated with CDK4/6i in Spanish real-world setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
445P - Tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A multicenter real-world study
Presenter: Chunxiao Sun
Session: Poster session 03